A phase I, open-label, multicentre, first-in-human study to evaluate safety, pharmacokinetics and efficacy of AMG 404, a PD-1 inhibitor, in patients with advanced solid tumours
Authors
Jose Gerard Monzon
Min Hee Hong (ORCID: https://orcid.org/0000-0003-3490-2195)
Mira Kistler
Mun N. Hui (ORCID: https://orcid.org/0000-0003-3238-0119)
Caio M. Rocha Lima
Wenqi Shi (ORCID: https://orcid.org/0000-0001-8972-7342)
A phase I, open-label, multicentre, first-in-human study to evaluate safety, pharmacokinetics and efficacy of AMG 404, a PD-1 inhibitor, in patients with advanced solid tumours
Jose Gerard Monzon, Min Hee Hong, Mira Kistler, Mun N. Hui et al.
Journal
BMJ Open
Topics
Cancer Immunotherapy and Biomarkers
article
A phase I, open-label, multicentre, first-in-human study to evaluate safety, pharmacokinetics and efficacy of AMG 404, a PD-1 inhibitor, in patients with advanced solid tumours
Jose Gerard Monzon, Min Hee Hong, Mira Kistler, Mun N. Hui, Caio M. Rocha Lima, Wenqi Shi, Ryota Shibaki, Vivek Subbiah, Hans Prenen, Rafał Dziadziuszko, Yasutoshi Kuboki, Timothy Price, Gerald S. Falchook, Hansen Wong, Sant P. Chawla, Antreas Hindoyan, Kejia Wang, Daniel Tan, Hendrik-Tobias Arkenau, Iwona Ługowska
article en
Abstract
No abstract available for this paper.
Publication Tag
BMJ OpenVol. 15(5)
Institutions
Atrium Health Wake Forest Baptist (US), Amgen (United States) (US), The University of Texas MD Anderson Cancer Center (US), SingHealth (SG), Sarah Cannon Research Institute (GB), Wakayama Medical University (JP), Yonsei University (KR), Chris O’Brien Lifehouse (AU), SingHealth Duke-NUS Academic Medical Centre (SG), Queen Elizabeth Hospital (AU), Sarah Cannon (US), Antwerp University Hospital (BE), Sarcoma Oncology Center (US), HealthONE (US), National Cancer Centre Singapore (SG), National Cancer Center Hospital East (JP), The Maria Sklodowska-Curie National Research Institute of Oncology (PL), Gdańsk Medical University (PL)